Barclays Downgrades Revance Therapeutics to Equal-Weight, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Balaji Prasad has downgraded Revance Therapeutics from Overweight to Equal-Weight and reduced the price target from $10 to $7.

September 13, 2024 | 7:46 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Barclays has downgraded Revance Therapeutics from Overweight to Equal-Weight and lowered the price target from $10 to $7, indicating a less optimistic outlook.
The downgrade from Overweight to Equal-Weight by Barclays suggests a less favorable view on Revance Therapeutics' stock, which is likely to lead to a negative short-term impact on its stock price. The reduction in the price target from $10 to $7 further supports this outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100